Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 13,920 shares of Twist Bioscience stock in a transaction on Friday, September 10th. The stock was sold at an average price of $118.01, for a total transaction of $1,642,699.20. Following the completion of the transaction, the chief executive officer now directly owns 234,810 shares in the company, valued at $27,709,928.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Emily M. Leproust also recently made the following trade(s):
- On Monday, July 12th, Emily M. Leproust sold 2,000 shares of Twist Bioscience stock. The stock was sold at an average price of $125.85, for a total transaction of $251,700.00.
NASDAQ TWST opened at $114.08 on Wednesday. The company has a market capitalization of $5.62 billion, a PE ratio of -39.89 and a beta of 0.70. The company has a fifty day moving average of $113.90 and a 200 day moving average of $118.00. Twist Bioscience Co. has a 1 year low of $59.26 and a 1 year high of $214.07.
Several institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP purchased a new stake in shares of Twist Bioscience during the fourth quarter worth about $1,774,000. US Bancorp DE grew its stake in Twist Bioscience by 5,791.3% during the 1st quarter. US Bancorp DE now owns 4,065 shares of the company’s stock valued at $503,000 after acquiring an additional 3,996 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in Twist Bioscience during the 1st quarter valued at about $27,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Twist Bioscience by 51.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,905 shares of the company’s stock valued at $731,000 after acquiring an additional 2,006 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Twist Bioscience by 33.2% during the 1st quarter. The Manufacturers Life Insurance Company now owns 26,115 shares of the company’s stock valued at $3,235,000 after acquiring an additional 6,504 shares in the last quarter. Institutional investors and hedge funds own 96.88% of the company’s stock.
Several research firms have recently commented on TWST. Robert W. Baird lowered their price objective on shares of Twist Bioscience from $140.00 to $130.00 and set an “outperform” rating for the company in a research note on Monday, August 9th. The Goldman Sachs Group began coverage on shares of Twist Bioscience in a research note on Friday, June 4th. They set a “neutral” rating and a $110.00 price objective for the company. William Blair began coverage on shares of Twist Bioscience in a research note on Tuesday, June 29th. They set an “outperform” rating for the company. Finally, Zacks Investment Research upgraded shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, September 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $118.00.
Twist Bioscience Company Profile
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage.
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.